Table S1, S3, S6-9 from Neoadjuvant BO-112 and Hypofractionated Radiation Therapy with or without Nivolumab in Soft-Tissue Sarcoma: Preclinical and Phase I Results

Le résumé fourni par la source

Supplementary Data is an excel file with supplementary tables S1, S3, and S6-S9 compiled. Supplemental Table 1 shows complete adverse events and relatedness to BO-112 or nivolumab by cohort. Supplemental Table 3 shows overall treatment emergent adverse events. Supplemental Table 6 shows key genes for annotation of myeloid clusters in scRNA-seq. Supplemental Table 7 shows top 100 differentially expressed genes for each myeloid cluster. Supplemental Table 8 shows annotation of T cell subsets by top differentially expressed genes. Supplemental Table 9 shows representativeness of Study Participants

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.